Medicine and Dentistry
Ganglioglioma
100%
Vincristine
100%
Lomustine
100%
Procarbazine
100%
Temozolomide
52%
Quality of Life
29%
Randomized Controlled Trial
29%
Progression Free Survival
23%
Arm
17%
Recurrent Disease
17%
Overall Survival
17%
Adverse Event
17%
Neuro-Oncology
17%
Hazard Ratio
11%
Clinical Trial
5%
Supportive Care
5%
Controlled Clinical Trial
5%
Meta-Analysis
5%
Second-Line Chemotherapy
5%
Clinical Oncology
5%
Critical Appraisal
5%
Treatment Option
5%
Pharmacology, Toxicology and Pharmaceutical Science
Lomustine
100%
Procarbazine
100%
Vincristine
100%
Chemotherapy
58%
Temozolomide
52%
Randomized Controlled Trial
29%
Progression Free Survival
23%
Overall Survival
17%
Recurrent Disease
17%
Adverse Event
17%
Clinical Trial
5%
Controlled Clinical Trial
5%
Second-Line Chemotherapy
5%
Nitrosourea
5%
Nursing and Health Professions
Procarbazine
100%
Vincristine
100%
Lomustine
100%
Temozolomide
52%
Quality of Life
29%
Progression Free Survival
23%
Adverse Event
17%
Recurrent Disease
17%
Overall Survival
17%
Practice Guideline
11%
Hazard Ratio
11%
Sample Size
5%
Health Care Quality
5%
National Health Organization
5%
Meta Analysis
5%
Cochrane Library
5%
Embase
5%
Critical Appraisal
5%
Nitrosourea
5%
World Health Organization
5%